Identification of a Novel Gene ARNT2 for Osteogenic Differentiation of Mesenchymal Stem Cells
Ding M., Hu Z., Pei K., Hu J., Liao Y., Cai C.
Laboratory Study, published in Calcif Tissue Int (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Calcif Tissue Int (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40679635
- PMCID
- PMC12274243
- DOI
- 10.1007/s00223-025-01407-4
Abstract (original English)
The balance between adipogenesis and osteogenesis in mesenchymal stem cells (MSCs) is pivotal for the maintenance of bone homeostasis. However, the genes responsible for regulating this balance are still not fully understood. This investigation sought to explore and identify novel genes that influence MSC differentiation into adipogenic and osteogenic lineages, thereby enhancing bone formation. Four datasets from the Gene Expression Omnibus (GEO) database were utilized: three focused on osteogenic differentiation (GSE73087, GSE18043, GSE114117), and one on adipogenic differentiation (GSE37836). Differentially expressed genes (DEGs) during both osteogenic and adipogenic differentiation processes were analyzed using the limma R package. A sum of 471 common differentially expressed genes (CDEGs) were found in MSC osteogenesis, comprising 240 elevated and 231 reduced genes. Similarly, in MSCs adipogenesis, 204 elevated genes and 459 reduced genes were identified. Fourteen hub genes were found to overlap between the CDEGs associated with MSC osteogenesis and DEGs linked to adipogenic differentiation. Notably, the expression of aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) was elevated during osteogenesis but reduced during adipogenesis. Overexpression of ARNT2 enhanced the expression of osteogenic markers in MSCs, while its suppression led to a decrease in osteogenic mark
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.